| 國立成功大學 |
2023 |
Neoadjuvant pegylated liposomal doxorubicin- and epirubicin-based combination therapy regimens for early breast cancer: a multicenter retrospective case–control study
|
Tsai, J.-H.;Li, C.-L.;Yeh, D.-C.;Hung, C.-S.;Hung, C.-C.;Lin, C.-Y.;Kuo, Y.-L. |
| 臺大學術典藏 |
2022-08-23T02:35:03Z |
Neoadjuvant afatinib with paclitaxel for triple-negative breast cancer and the molecular characteristics in responders and non-responders
|
Dai M.-S.; Liu L.-C.; Wang M.-Y.; Lo C.; Chang S.; Tan K.T.; Chen S.-J.; SUNG-HSIN KUO; Huang C.-S.; Yeh D.-C.; Tseng L.-M.; Lee Y.-H.; Chen S.-T.; Lin P.-H. |
| 臺大學術典藏 |
2022-08-12T06:27:35Z |
EORTC QLQ-BM22 quality of life evaluation and pain outcome in patients with bone metastases from breast cancer treated with zoledronic acid
|
Yeh D.-C.; Chen D.-R.; Chao T.-Y.; Chen S.-C.; Wang H.-C.; Rau K.-M.; Feng Y.-H.; Chang Y.-C.; Lee K.-D.; Ou-Yang F.; Kuo W.-H.; KING-JEN CHANG; Lin Y.-C.; Tseng L.-M.; Hou M.-F. |
| 臺大學術典藏 |
2022-07-29T03:18:01Z |
Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients
|
Lin P.-H.; Chen S.-C.; Tseng L.-M.; Chang K.-J.; Huang A.-C.; Cheng K.-C.; Yang K.; Wu H.-C.; Chao T.-Y.; Chang Y.-C.; Lin P.-C.; Kuo W.-H.; Kuo W.-L.; Lin C.-H.; Chen H.-M.; Yeh D.-C.; Liu L.-C.; Liu C.-Y.; MING-YANG WANG; Lo C.; Lu Y.-S.; Huang C.-S. |
| 臺大學術典藏 |
2022-07-29T03:18:01Z |
Neoadjuvant afatinib with paclitaxel for triple-negative breast cancer and the molecular characteristics in responders and non-responders
|
Lin P.-H.; Tseng L.-M.; Lee Y.-H.; Chen S.-T.; Yeh D.-C.; Dai M.-S.; Liu L.-C.; MING-YANG WANG; Lo C.; Chang S.; Tan K.T.; Chen S.-J.; Kuo S.-H.; Huang C.-S. |
| 臺大學術典藏 |
2022-05-11T08:25:41Z |
Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients
|
Lin P.-H.; Chen S.-C.; Tseng L.-M.; Chang K.-J.; Huang A.-C.; Cheng K.-C.; Yang K.; Wu H.-C.; Chao T.-Y.; Chang Y.-C.; Lin P.-C.; Kuo W.-H.; Kuo W.-L.; CHING-HUNG LIN; Chen H.-M.; Yeh D.-C.; Liu L.-C.; Liu C.-Y.; Wang M.-Y.; Lo C.; Lu Y.-S.; Huang C.-S. |
| 臺大學術典藏 |
2022-03-15T05:39:30Z |
Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy
|
Lu Y.-S.; WEI-WU CHEN; Lin C.-H.; Yeh D.-C.; Tseng L.-M.; Wu P.-F.; Rau K.-M.; Chen B.-B.; Chao T.-C.; Huang S.-M.; Huang C.-S.; Shih T.T.-F.; Cheng A.-L.; Taiwan Breast Cancer Consortium |
| 臺大學術典藏 |
2022-03-15T05:39:29Z |
A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis
|
Wu P.-F.; Lin C.-H.; Kuo C.-H.; WEI-WU CHEN; Yeh D.-C.; Liao H.-W.; Huang S.-M.; Cheng A.-L.; Lu Y.-S. |
| 臺大學術典藏 |
2022-03-15T05:39:25Z |
A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer
|
WEI-WU CHEN; Yeh D.-C.; Chao T.-Y.; Lin C.-H.; Chow L.W.-C.; Chang D.-Y.; Hsieh Y.-Y.; Huang S.-M.; Cheng A.-L.; Lu Y.-S.; Taiwan Breast Cancer Consortium |
| 臺大學術典藏 |
2022-03-10T02:31:33Z |
Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients
|
PO-HAN LIN; Chen S.-C.; Tseng L.-M.; Chang K.-J.; Huang A.-C.; Cheng K.-C.; Yang K.; Wu H.-C.; Chao T.-Y.; Chang Y.-C.; Lin P.-C.; Kuo W.-H.; Kuo W.-L.; Lin C.-H.; Chen H.-M.; Yeh D.-C.; Liu L.-C.; Liu C.-Y.; Wang M.-Y.; Lo C.; Lu Y.-S.; Huang C.-S. |
| 國立成功大學 |
2022 |
Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients
|
Lin, P.-H.;Chen, S.-C.;Tseng, L.-M.;Chang, K.-J.;Huang, A.-C.;Cheng, K.-C.;Yang, K.;Wu, H.-C.;Chao, T.-Y.;Chang, Y.-C.;Lin, P.-C.;Kuo, W.-H.;Kuo, W.-L.;Lin, C.-H.;Chen, H.-M.;Yeh, D.-C.;Liu, Liu L.-C.;Liu, C.-Y.;Wang, M.-Y.;Lo, C.;Lu, Y.-S.;Huang, C.-S. |
| 臺大學術典藏 |
2021-08-31T06:29:51Z |
A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis
|
Wu P.-F.; Lin C.-H.; Kuo C.-H.; Chen W.-W.; Yeh D.-C.; Liao H.-W.; Huang S.-M.; ANN-LII CHENG; Lu Y.-S. |
| 臺大學術典藏 |
2021-08-31T06:29:51Z |
Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy
|
Lu Y.-S.; Chen T.W.-W.; Lin C.-H.; Yeh D.-C.; Tseng L.-M.; Wu P.-F.; Rau K.-M.; Chen B.-B.; Chao T.-C.; Huang S.-M.; Huang C.-S.; Shih T.T.-F.; ANN-LII CHENG; Taiwan Breast Cancer Consortium |
| 臺大學術典藏 |
2021-08-31T06:29:30Z |
A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer
|
Chen T.W.-W.; Yeh D.-C.; Chao T.-Y.; Lin C.-H.; Chow L.W.-C.; Chang D.-Y.; Hsieh Y.-Y.; Huang S.-M.; ANN-LII CHENG; Lu Y.-S.; Taiwan Breast Cancer Consortium |
| 臺大學術典藏 |
2021-07-28T06:46:45Z |
A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis
|
Wu P.-F.; CHING-HUNG LIN; Kuo C.-H.; Chen W.-W.; Yeh D.-C.; Liao H.-W.; Huang S.-M.; Cheng A.-L.; Lu Y.-S. |
| 臺大學術典藏 |
2021-06-04T06:23:20Z |
A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis
|
Wu P.-F.; Lin C.-H.; CHING-HUA KUO; Chen W.-W.; Yeh D.-C.; Liao H.-W.; Huang S.-M.; Cheng A.-L.; Lu Y.-S. |
| 臺大學術典藏 |
2021-03-18T03:23:37Z |
A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis
|
Wu P.-F.; Lin C.-H.; Kuo C.-H.; WEI-WU CHEN; Yeh D.-C.; Liao H.-W.; Huang S.-M.; Cheng A.-L.; Lu Y.-S. |
| 臺大學術典藏 |
2021-03-18T03:23:37Z |
Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy
|
Lu Y.-S.; WEI-WU CHEN; Lin C.-H.; Yeh D.-C.; Tseng L.-M.; Wu P.-F.; Rau K.-M.; Chen B.-B.; Chao T.-C.; Huang S.-M.; Huang C.-S.; Shih T.T.-F.; Cheng A.-L.; Taiwan Breast Cancer Consortium |
| 臺大學術典藏 |
2021-03-18T03:23:34Z |
A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer
|
WEI-WU CHEN; Yeh D.-C.; Chao T.-Y.; Lin C.-H.; Chow L.W.-C.; Chang D.-Y.; Hsieh Y.-Y.; Huang S.-M.; Cheng A.-L.; Lu Y.-S.; Taiwan Breast Cancer Consortium |
| 臺大學術典藏 |
2021-03-15T06:27:31Z |
A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer
|
Chen T.W.-W.; Yeh D.-C.; Chao T.-Y.; Lin C.-H.; Chow L.W.-C.; DWANG-YING CHANG; Hsieh Y.-Y.; Huang S.-M.; Cheng A.-L.; Lu Y.-S.; Taiwan Breast Cancer Consortium |
| 臺大學術典藏 |
2021-02-23T08:26:33Z |
Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer
|
Lu Y.-S.; Chen D.-R.; Tseng L.-M.; Yeh D.-C.; Chen S.-T.; Hsieh C.-M.; Wang H.-C.; Yeh H.-T.; SUNG-HSIN KUO; Huang C.-S. |
| 臺大學術典藏 |
2020-08-06T07:51:48Z |
Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy
|
Lu Y.-S.;Chen T.W.-W.;Lin C.-H.;Yeh D.-C.;Tseng L.-M.;Wu P.-F.;Rau K.-M.;Chen B.-B.;Chao T.-C.;Huang S.-M.;Huang C.-S.;Tiffany Ting-Fang Shih;Cheng A.-L.;Taiwan Breast Cancer Consortium; Lu Y.-S.; Chen T.W.-W.; Lin C.-H.; Yeh D.-C.; Tseng L.-M.; Wu P.-F.; Rau K.-M.; Chen B.-B.; Chao T.-C.; Huang S.-M.; Huang C.-S.; TIFFANY TING-FANG SHIH; Cheng A.-L.; Taiwan Breast Cancer Consortium |
| 臺大學術典藏 |
2020-05-25T06:52:00Z |
Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer
|
Yen-Shen Lu;Chen D.-R;Tseng L.-M;Yeh D.-C;Chen S.-T;Hsieh C.-M;Wang H.-C;Yeh H.-T;Kuo S.-H;Huang C.-S.; YEN-SHEN LU; Chen D.-R; Tseng L.-M; Yeh D.-C; Chen S.-T; Hsieh C.-M; Wang H.-C; Yeh H.-T; Kuo S.-H; Huang C.-S. |
| 臺大學術典藏 |
2020-05-25T06:51:53Z |
Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy
|
Shih T.T.-F; Cheng A.-L; Taiwan Breast Cancer Consortium; Huang C.-S; Huang S.-M; Chao T.-C; Chen B.-B; Rau K.-M; Wu P.-F; Tseng L.-M; Yeh D.-C; Lin C.-H; Chen T.W.-W; YEN-SHEN LU; Taiwan Breast Cancer Consortium;Cheng A.-L;Shih T.T.-F;Huang C.-S;Huang S.-M;Chao T.-C;Chen B.-B;Rau K.-M;Wu P.-F;Tseng L.-M;Yeh D.-C;Lin C.-H;Chen T.W.-W;Yen-Shen Lu |
| 臺大學術典藏 |
2020-05-25T06:51:53Z |
A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis
|
Wu P.-F; Lin C.-H; Kuo C.-H; Chen W.-W; Yeh D.-C; Liao H.-W; Huang S.-M; Cheng A.-L; YEN-SHEN LU; Wu P.-F;Lin C.-H;Kuo C.-H;Chen W.-W;Yeh D.-C;Liao H.-W;Huang S.-M;Cheng A.-L;Yen-Shen Lu |
| 臺大學術典藏 |
2020-03-23T07:19:02Z |
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): An open-label, randomised, phase 3 trial
|
Biakhov M.; Chovanec J.; Harris J.; Caranana V.; Lopez R.; Tusquets I.; Chang T.-W.; Liu M.-C.; Altundag K.; Gokmen E.; Avery T.; Chan D.; Kendall S.; Hetzel D.; Kass F.; Singh J.; The LUX-Breast 1 study group; Pais A.; Damasceno M.; Wysocki P.; Szczylik C.; Blasinska-Morawiec M.; Palominos O.M.; van den Bosch J.; Tjan-Heijnen V.C.G.; Honkoop A.; Dercksen M.W.; Luna G.A.; Nakayama T.; Kudaba I.; Fried G.; Isacson R.; Mohan R.; Nag S.; Krishnan S.; Bhattacharyya G.S.; O'brien M.; Adamson D.; Kristeleit H.; Paepke S.; Otremba B.; Kurbacher C.M.; Hannig C.V.; Fett W.; Barinoff J.; Augustin D.; Petit T.; Lortholary A.; Espie M.; Snyder R.; Noryk D.; Graas M.-P.; Aleixo S.; Caleffi M.; Franke F.; Hegg R.; Santi P.X.; Vinholes J.; Zereu M.; Ghedira S.; Poirier E.; Yelle L.; Yanez E.; Liu J.; Luo R.; Pecha V.; Petruzelka L.; Azim H.A.; Shamaa S.S.; Brain E.; Chauffert B.; Lerzo G.; Chan A.; Carraro S.; Lawler W.; Chang H.-T.; Kaplan E.; Cao M.G.; Chen S.-T.; Chacon J.I.; Rapoport B.; Pienaar R.; Maart K.; Harbeck N.;Chiun-Sheng Huang;Hurvitz S.;Yeh D.-C.;Shao Z.;Im S.-A.;Jung K.H.;Shen K.;Ro J.;Jassem J.;Zhang Q.;Im Y.-H.;Wojtukiewicz M.;Sun Q.;Chen S.-C.;Goeldner R.-G.;Uttenreuther-Fischer M.;Xu B.;Piccart-Gebhart M.;Krasnozhon D.;Tong Z.;Arora R.S.;Jacob L.A.;Staroslawska E.;Wang X.;Satya Suresh Attili V.;Mehta A.O.;Lee S.H.;Tseng M.-L.;Perera N.A.M.;Huizing M.;Melichar B.;Grigiene R.;Bharwani L.;Cortes J.;Garcia M.;Chirgwin J.;Baranau Y.;Ermakov N.;Li W.;Lin T.;Qin S.;Shen P.;Yang J.;Dohollou N.;Kerbrat P.;Uleer C.;Kristeleit H.;Nagarkar R.V.;Crown J.;Kelly C.;Kaufman B.;Ionta M.T.;Park K.H.;Farhat F.;Chin L.S.;Sufliarsky J.;Saenz J.A.G.;Begbie S.;Dittrich C.;Karchmit Y.;Awada A.;Bines J.;Rigo R.;Califaretti N.;Sridhar S.;Villa D.;Jiang Z.;Wang X.;Wu G.;Shu W.;Zheng H.;Delva R.;Pivot X.;Beckmann M.;Bischoff J.;Gerber B.;Maass N.;Richters L.;Schumacher C.;Jain M.M.;Indelli M.;Purkalne G.;Juozaityte E.;Erdkamp F.L.G.;Sanchez F.S.;Susko-Kazamowicz M.;Sousa S.;Mukhametshina G.;Shomova M.;Yap Y.S.;Beniak J.;Grasic C.;Demetriou G.;Maart K.;Pienaar R.;Rapoport B.;Chacon J.I.;Cao M.G.;Chen S.-T.;Chang H.-T.;Kaplan E.;Lawler W.;Carraro S.;Lerzo G.;Chan A.;Snyder R.;Noryk D.;Graas M.-P.;Aleixo S.;Caleffi M.;Franke F.;Hegg R.;Santi P.X.;Vinholes J.;Zereu M.;Ghedira S.;Poirier E.;Yelle L.;Yanez E.;Liu J.;Luo R.;Pecha V.;Petruzelka L.;Azim H.A.;Shamaa S.S.;Brain E.;Chauffert B.;Espie M.;Lortholary A.;Petit T.;Augustin D.;Barinoff J.;Fett W.;Hannig C.V.;Kurbacher C.M.;Otremba B.;Paepke S.;Adamson D.;Kristeleit H.;O'Brien M.;Bhattacharyya G.S.;Krishnan S.;Mohan R.;Nag S.;Fried G.;Isacson R.;Nakayama T.;Kudaba I.;Luna G.A.;Dercksen M.W.;Honkoop A.;Tjan-Heijnen V.C.G.;Van Den Bosch J.;Palominos O.M.;Blasinska-Morawiec M.;Szczylik C.;Wysocki P.;Damasceno M.;Pais A.;Biakhov M.;Chovanec J.;Harris J.;Caranana V.;Lopez R.;Tusquets I.;Chang T.-W.;Liu M.-C.;Altundag K.;Gokmen E.;Avery T.;Chan D.;Kendall S.;Hetzel D.;Kass F.;Singh J.;The Lux-Breast 1 Study Group; Mehta A.O.; Satya Suresh Attili V.; Wang X.; Staroslawska E.; Arora R.S.; Jacob L.A.; Tong Z.; Krasnozhon D.; Piccart-Gebhart M.; Xu B.; Uttenreuther-Fischer M.; Goeldner R.-G.; Chen S.-C.; Sun Q.; Wojtukiewicz M.; Im Y.-H.; Harbeck N.; CHIUN-SHENG HUANG; Hurvitz S.; Yeh D.-C.; Shao Z.; Im S.-A.; Jung K.H.; Shen K.; Ro J.; Jassem J.; Zhang Q.; Dittrich C.; Begbie S.; Saenz J.A.G.; Sufliarsky J.; Farhat F.; Chin L.S.; Park K.H.; Ionta M.T.; Kaufman B.; Kelly C.; Crown J.; Lee S.H.; Tseng M.-L.; Perera N.A.M.; Huizing M.; Melichar B.; Grigiene R.; Bharwani L.; Cortes J.; Garcia M.; Chirgwin J.; Baranau Y.; Ermakov N.; Li W.; Lin T.; Qin S.; Shen P.; Yang J.; Dohollou N.; Kerbrat P.; Uleer C.; Kristeleit H.; Nagarkar R.V.; Demetriou G.; Grasic C.; Beniak J.; Yap Y.S.; Shomova M.; Sousa S.; Mukhametshina G.; Susko-Kazamowicz M.; Sanchez F.S.; Erdkamp F.L.G.; Juozaityte E.; Purkalne G.; Indelli M.; Jain M.M.; Schumacher C.; Richters L.; Maass N.; Gerber B.; Bischoff J.; Beckmann M.; Karchmit Y.; Awada A.; Bines J.; Rigo R.; Califaretti N.; Sridhar S.; Villa D.; Jiang Z.; Wang X.; Wu G.; Shu W.; Zheng H.; Delva R.; Pivot X. |
| 中山醫學大學 |
2019-12 |
Association of functional dorsal attention network alterations with breast cancer and chemotherapy
|
Shen, C.-Y.; Chen, V.C.-H.; Yeh, D.-C.; Huang, S.-L.; Zhang, X.-R.; Chai, J.-W.; Huang, Y.-H.; Chou, M.-C.; Weng, J.-C. |
| 中山醫學大學 |
2019-03 |
Association of functional dorsal attention network alterations with breast cancer and chemotherapy
|
Shen, C.-Y.; Yeh, D.-C.; Huang, S.-L.; Zhang, X.-R.; Chai, J.-W.; Huang, Y.-H.; Chou, M.-C.; Weng, J.-C. |
| 臺大學術典藏 |
2018 |
A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer
|
Chen T.W.-W; Yeh D.-C; Chao T.-Y; Lin C.-H; Chow L.W.-C; Chang D.-Y; Hsieh Y.-Y; Huang S.-M; Cheng A.-L; YEN-SHEN LU; Taiwan Breast Cancer Consortium; Chen T.W.-W;Yeh D.-C;Chao T.-Y;Lin C.-H;Chow L.W.-C;Chang D.-Y;Hsieh Y.-Y;Huang S.-M;Cheng A.-L;Yen-Shen Lu;Taiwan Breast Cancer Consortium |
| 臺大學術典藏 |
2017 |
Evaluation of the association between quantitative mammographic density and breast cancer occurred in different quadrants
|
RUEY-FENG CHANG; Su, M.-Y.; Kwong, J.; Yeh, L.-R.; Chang, R.-F.; Yeh, D.-C.; Chang, R.; Li, S.; Chan, S.; Chen, J.-H.; Chan, S.;Chen, J.-H.;Li, S.;Chang, R.;Yeh, D.-C.;Chang, R.-F.;Yeh, L.-R.;Kwong, J.;Su, M.-Y. |
| 臺大學術典藏 |
2015 |
Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy
|
Cheng A.-L.; Shih T.T.-F.; CHIUN-SHENG HUANG; Huang S.-M.; Chao T.-C.; Chen B.-B.; Rau K.-M.; Lu Y.-S.; Chen T.W.-W.; Lin C.-H.; Yeh D.-C.; Tseng L.-M.; Wu P.-F.; Taiwan Breast Cancer Consortium |
| 國立政治大學 |
2013-04 |
Mental adjustment at different phases in breast cancer trajectory: Re-examination of factor structure of the Mini-MAC and its correlation with distress
|
Wang, Wei-Ting;Tu, P.-C.;Liu, T.-J.;Yeh, D.-C.;Hsu, W.-Y.; 王瑋婷;涂珮瓊 |
| 臺大學術典藏 |
2011 |
Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer
|
Lu Y.-S.;Chen D.-R.;Tseng L.-M.;Yeh D.-C.;Chen S.-T.;Hsieh C.-M.;Wang H.-C.;Yeh H.-T.;Kuo S.-H.;Chiun-Sheng Huang; Lu Y.-S.; Chen D.-R.; Tseng L.-M.; Yeh D.-C.; Chen S.-T.; Hsieh C.-M.; Wang H.-C.; Yeh H.-T.; Kuo S.-H.; CHIUN-SHENG HUANG |
